Get the Stockscreener App
2.03
2.53%
0.05
After Hours:
2.00
-0.03
-1.48%
Neurosense Therapeutics Ltd stock is traded at $2.03, with a volume of 118.07K.
It is up +2.53% in the last 24 hours and down -17.14% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.98
Open:
$2.07
24h Volume:
118.07K
Relative Volume:
0.43
Market Cap:
$50.14M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-2.1828
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
-2.87%
1M Performance:
-17.14%
6M Performance:
+81.25%
1Y Performance:
+131.08%
1-Day Range:
$1.94
$2.07
1-Week Range:
$1.9202
$2.17
52-Week Range:
$0.512
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
2.03 | 50.14M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyEntry Level Low Risk Picks - Newser
What makes NeuroSense Therapeutics Ltd. stock price move sharplyMassive Profit Potential - Newser
How NeuroSense Therapeutics Ltd. stock performs during market volatilityProven Trading Plan - Newser
Why NeuroSense Therapeutics Ltd. Equity Warrant stock attracts strong analyst attentionExpert Backed Predictions - Newser
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs during market volatilityGrowth Optimized Stock Radar - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionHigh Return Intraday Picks - Newser
D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Releases Q2 2025 Corporate Update - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading 0.5% Higher – Here’s What Happened - Defense World
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval - TipRanks
NRSN: Health Canada Meeting Advances PrimeC Toward Expedited ALS Approval - Stock Titan
NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday - Defense World
Why It Makes Sense To Keep An Eye On NeuroSense Therapeutics - RTTNews
NeuroSense Stock Soars 10.33% on ALS Treatment Commercialization Plans - AInvest
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Top Nasdaq Companies by Market Cap Ranked by Kalkine - Kalkine Media
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 1.2% – Here’s What Happened - Defense World
Citadel Advisors LLC Buys 219,717 Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - mx.advfn.com
NRSN stock touches 52-week high at $1.65 amid robust gains - Investing.com
NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia
D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga
Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus
Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com
Amyotrophic Lateral Sclerosis Market Set for Groundbreaking - openPR.com
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - Yahoo Finance
NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):